Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNexus Gene Lab (BGLC) Return on Equity (2019 - 2025)

BioNexus Gene Lab's Return on Equity history spans 7 years, with the latest figure at 0.32% for Q3 2025.

  • For Q3 2025, Return on Equity fell 21.0% year-over-year to 0.32%; the TTM value through Sep 2025 reached 0.32%, down 21.0%, while the annual FY2024 figure was 0.18%, 14.0% up from the prior year.
  • Return on Equity for Q3 2025 was 0.32% at BioNexus Gene Lab, up from 0.4% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.11% in Q4 2021 and bottomed at 0.4% in Q2 2025.
  • The 5-year median for Return on Equity is 0.08% (2023), against an average of 0.12%.
  • The largest annual shift saw Return on Equity crashed -39bps in 2023 before it increased 29bps in 2024.
  • A 5-year view of Return on Equity shows it stood at 0.11% in 2021, then plummeted by -135bps to 0.04% in 2022, then plummeted by -610bps to 0.27% in 2023, then rose by 29bps to 0.19% in 2024, then plummeted by -66bps to 0.32% in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Return on Equity are 0.32% (Q3 2025), 0.4% (Q2 2025), and 0.28% (Q1 2025).